You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT, LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Spirulina-based oral malaria vaccine

    SBC: Lumen Bioscience, Inc.            Topic: NIAID

    ABSTRACT Vaccination represents the single most effective and cost effective medical intervention devised to datesaving lives and reducing morbidity and disability for billions of humansDespite the early success of the oral polio vaccinemost vaccines are delivered parenterallyand as such are associated with painnon compliancebiohazardous medical waste and strict requirements for expensive producti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Highly Sensitive Chimerism Testing to Detect Early Leukemia Relapse Post-Allo-Transplantation

    SBC: Chimerocyte, Inc.            Topic: 102

    ABST RACT Patients with acute blood malignancies who undergo allogeneic hematopoietic stem cell transplantationHSCTare monitored for minimal residual diseaseMRDas predictive of relapseIncreasing mixed chimerismreemerging recipient cellscorrelates with reappearance of underlying disease by association with MRDGenetic and immunophenotypic heterogeneity of these malignancies often prevents establishi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Treatment for Acetominophen-Induced Liver Injury

    SBC: Mitotherapeutix LLC            Topic: 300

    Abstract The Specific Aim of this Phase I STTR proposal is to test the feasibility of blocking MCJalso called DnaJCto overcome acute acetaminophen liver toxicityAcetaminophen or APAPfrom acetyl paraaminophenolis a common drug used to address pain and feverIn the US aloneaboutpatients per year are admitted to intensive care units with APAP induced liver injury and close toof these patients undergo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure

    SBC: ToleRaM NanoTech LLC            Topic: NIBIB

    ABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus

    SBC: L2 Diagnostics, LLC            Topic: NIAMS

    ABSTRACT Systemic autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus are characterized by polyclonal T cell activation driving the production of pathogenic class switched autoantibodiesThe class switchedsomatically mutated antibodies are generated from germinal centerGCB cellsA subset of effector CDT cellsknown as T follicular helperTfhcellshas been shown to play an ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government